Clozapine‐Associated Neutropenia With COVID‐19 Infection and the Role of Filgrastim
Progress in Neurology and Psychiatry · 2026-11 · 30 (4)
DOI: 10.1002/pnp.70019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Progress in Neurology and Psychiatry, online erschienen am 17.10.2026. Verfasst von Devender Singh Yadav. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Clozapine is the gold standard, evidence‐based treatment of choice for treatment‐resistant schizophrenia. However, clozapine can induce serious, life‐threatening adverse effects, including neutropenia and agranulocytosis. There is accumulating evidence to suggest that rechallenging with clozapine should be considered in most patients with clozapine‐associated neutropenia (mild to moderate neutropenia) who do not respond to other treatments. Ruling out other causes of coincidental neutropenia is important when the neutropenia occurs after 2 years of treatment on clozapine, as the risk of developing neutropenia becomes negligible after 2 years and becomes nonspecific to clozapine. When our patient developed neutropenia whilst taking clozapine during Covid‐19 infection, she benefitted from Filgrastim [a Granulocyte‐Colony Stimulating Factor (G‐CSF)], which provided symptomatic treatment.
Zitieren
APA
Yadav, D. S. (2026). Clozapine‐Associated Neutropenia With COVID‐19 Infection and the Role of Filgrastim. Progress in Neurology and Psychiatry, 30(4). https://doi.org/10.1002/pnp.70019
Vancouver
Yadav DS. Clozapine‐Associated Neutropenia With COVID‐19 Infection and the Role of Filgrastim. Progress in Neurology and Psychiatry. 2026;30(4). doi:10.1002/pnp.70019
BibTeX
@article{Yadav2026,
author = {Yadav, Devender Singh},
title = {Clozapine‐Associated Neutropenia With COVID‐19 Infection and the Role of Filgrastim},
journal = {Progress in Neurology and Psychiatry},
year = {2026},
volume = {30},
number = {4},
doi = {10.1002/pnp.70019}
}
EUVIMED